Electrical impedance myography has a strong correlation to motor unit number estimation in the ALS rat. The rate of decline in electrical impedance myography correlates strongly to life expectancy of the animals. Electrical impedance myography progresses linearly, consistent with human data collected thus far, and supporting its potential ease of application in ALS clinical trials.
h i g h l i g h t s
Electrical impedance myography has a strong correlation to motor unit number estimation in the ALS rat. The rate of decline in electrical impedance myography correlates strongly to life expectancy of the animals. Electrical impedance myography progresses linearly, consistent with human data collected thus far, and supporting its potential ease of application in ALS clinical trials.
a b s t r a c t
Objective: Human studies have shown that electrical impedance myography (EIM), a technique based on the surface application of high-frequency, low-intensity electrical current to localized areas of muscle, is sensitive to muscle denervation. In this study, we examined the role of EIM as a potential biomarker for assessing ALS disease progression in the SOD1 transgenic rat by comparing it to motor unit number estimation (MUNE). Methods: Multi-frequency EIM and MUNE were performed twice weekly in 16 rats from approximately 10 weeks of age onward. Four different EIM measures were evaluated, including the previously studied 50 kHz phase and three condensed multi-frequency parameters. Results: The rate of deterioration in the multi-frequency phase data from 100-500 kHz had the strongest correlation to survival (q = 0.79, p < 0.001), surpassing that of MUNE (q = 0.57, p = 0.020). These two measures were also strongly correlated (q = À0.94, p < 0.001) to one another. Conclusions: These findings support that EIM is an effective tool for assessing disease progression in the ALS rat. Significance: Given its ease of application and ability to assess virtually any superficial muscle, EIM deserves further study as a biomarker in human ALS clinical therapeutic trials. Ó 2011 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.
Introduction
Amyotrophic lateral sclerosis (ALS) remains a devastating disease with minimal effective therapy (Qureshi et al., 2009) . A major roadblock to the assessment of new treatments in ALS is the lack of effective, sensitive biomarkers (Cudkowicz et al., 2010) . A variety of radiological and serologic biomakers have been studied (Turner et al., 2009) . However, since the final common pathway of ALS is motor neuron loss and consequent muscle wasting, motor-specific markers would seem to offer a promising approach. Indeed, one technique, motor unit number estimation (MUNE), has been studied in ALS for more than three decades (Shefner and Gooch, 2003) .
The aim of MUNE is to approximate the number of motor neurons innervating a given muscle and is thus conceptually appealing (Dantes and McComas, 1991) . A variety of methods for performing MUNE have been developed, including the incremental (McComas et al., 1971) and multipoint techniques (Brown, 1972) . A combination of the two methods may offer better reproducibility and ease of application in clinical trials (Goyal et al., 2010; Shefner et al., 2011) . However, regardless of specific technique, MUNE suffers from several limitations, including its requiring considerable training and ongoing decision-making as data is collected, its ability to evaluate only a very limited set of distal muscles, and only fair repeatability early in the disease course (Felice, 1995) .
Electrical impedance myography (EIM) is another electrophysiological technique that holds promise for assessing ALS progression (Rutkove, 2009; Rutkove et al., 2007) . Unlike standard electrophysiological techniques, EIM is not directly dependent upon the inherent electrical potential of muscle or nerve tissue.
